1、Table of ContentsAs filed with the Securities and Exchange Commission on January 10,2025 Registration No._ UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549 FORM S-1 REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF 1933 COEPTIS THERAPEUTICS HOLDINGS,INC.(Exact name of registrant as

2、 specified in its charter)Delaware283498-1465952(State or other jurisdictionof incorporation)(Primary Standard IndustrialClassification Code Number)(I.R.S.EmployerIdentification No.)105 Bradford Road,Suite 420Wexford,Pennsylvania 15090724-934-6467(Address,including zip code and telephone number,incl

3、uding area code,of registrants principal executive offices)David MehalickChief Executive OfficerCoeptis Therapeutics Holdings,Inc.105 Bradford Road,Suite 420Wexford Pennsylvania 15090724-934-6467(Name,address,including zip code,and telephone number,including area code,of agent for service)_ Copy to:

4、Denis Dufresne,Esq.Meister Seelig&Fein PLLC125 Park Avenue,7th FloorNew York,New York 10017Tel:(212)655-3500Fax:(212)655-3535 Approximate date of commencement of proposed sale to the public:From time to time after the effective date of thisRegistration Statement.If any of the securities being regist

5、ered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 underthe Securities Act of 1933,check the following box.If this Form is filed to register additional securities for an offering pursuant to Rule 462(b)under the Securities Act,check thefollowing box and list th

6、e Securities Act registration statement number of the earlier effective registration statement for the sameoffering.If this Form is a post-effective amendment filed pursuant to Rule 462(c)under the Securities Act,check the following box and listthe Securities Act registration statement number of the